CRYSTAL ADAMS: Open Payments
NPI 1649604141 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,337 in 87 payments from 23 companies in 2025. Trend: 2023 $1,794 · 2024 $1,213 · 2025 $1,337
Food & beverage: $1,337
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $346 |
| AstraZeneca Pharmaceuticals LP | 9 | $184 |
| Amgen Inc. | 13 | $135 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Novo Nordisk Inc | 5 | $76 |
| SHIELD THERAPEUTICS INC | 2 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Verona Pharma, Inc. | 2 | $41 |
Products named: UBRELVY, AIRSUPRA, OTEZLA, Auvelity, QULIPTA, Wegovy, ACCRUFER, VRAYLAR.
Industry payments across AR — which companies pay providers there.
